Clinical

Dataset Information

0

Multicenter Phase II Study of FOLFOX Plus Bi-weekly Cetuximab as First Line Treatment in Patients with Metastatic Colorectal Cancer


ABSTRACT: Interventions: Chemotherapy regimen mFOLFOX6 +Cetuximab Cetuximab 500mg/m2/biweekly Oxaliplatin 85mg/m2/biweekly l-LV 200mg/m2/biweekly 5-FU/bolus 40mg/m2/biweekly 5-FU/infusional 2400mg/m2/biweekly ( day1-3:46h) Primary outcome(s): Response Rate Study Design: Single arm Non-randomized

DISEASE(S): Metastatic Colorectal Cancer

PROVIDER: 2621834 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2618714 | ecrin-mdr-crc
| 2621320 | ecrin-mdr-crc
| 2633522 | ecrin-mdr-crc
| 2633714 | ecrin-mdr-crc
| 2630670 | ecrin-mdr-crc
| 2630948 | ecrin-mdr-crc
| 2626017 | ecrin-mdr-crc
| 2618233 | ecrin-mdr-crc
| 2623200 | ecrin-mdr-crc
| 2622536 | ecrin-mdr-crc